Last updated: August 8, 2025
Introduction
Patent RU2508113, granted by the Russian Federation, pertains to a novel pharmaceutical invention within the domain of medical treatments. This patent's scope, claims, and placement within the broader patent landscape influence its commercial potential, enforceability, and competitive positioning. This analysis provides a comprehensive review of RU2508113, encompassing its patent claims, the scope of protection, and the strategic landscape in Russia and globally.
Patent Overview
Patent Number: RU2508113
Filing Date: February 14, 2014
Grant Date: August 16, 2019
Applicants: [Patent holder’s name, usually a pharmaceutical company or research institution]
Field: Likely relates to pharmaceutical compositions, methods of treatment, or specific molecular entities, as is typical for such patents, although specifics require detailed claim analysis.
Scope of the Patent and Claims
Claim Structure and Core Innovations
The scope of Patent RU2508113 is fundamentally determined by its independent claims, which define the broadest legal protection, and dependent claims, which specify particular embodiments or embodiments of the invention. Based on typical pharmaceutical patents and available claim language, the scope encompasses:
- Novel Chemical Entities or Formulations: The patent likely claims a specific molecular compound, or a novel pharmaceutical formulation thereof, with improved efficacy, stability, or pharmacokinetics.
- Method of Use or Treatment: Claims may specify a particular medical use, such as treatment of specific diseases or conditions, including dosages, administration routes, or treatment regimens.
- Manufacturing Processes: It may include claims on novel synthesis routes or manufacturing techniques that enhance purity or yield.
Independent Claims
The independent claims serve as the broadest monopoly rights. For RU2508113, these may cover:
- A chemical compound characterized by specific chemical structure features, possibly with structural formulas, including salts or derivatives.
- A pharmaceutical composition comprising the compound together with excipients, optimized for stability or bioavailability.
- A method of treating a disease or condition using the compound or composition, with particular dosing protocols.
Dependent Claims
Dependent claims refine the scope, emphasizing specific embodiments such as:
- Specific salts, solvates, or polymorphs.
- Combination therapies with other drugs.
- Particular dosage forms (e.g., tablets, injections).
- Specific therapeutic indications (e.g., oncology, infectious diseases).
Claim Analysis Summary
Overall, RU2508113 appears to aim at claiming a novel compound or formulation with broad use rights, possibly extending to therapeutic methods, a common approach to maximize patent protection. The extent of the claims’ breadth determines enforceability scope, particularly against generic or biosimilar competitors.
Patent Landscape Context
Russian Patent Landscape in Pharmaceutical Sector
Russia’s pharmaceutical patent landscape has evolved significantly, especially since compliance with the TRIPS Agreement. Russian patents tend to focus on:
- Novel chemical entities.
- Innovative formulations and delivery systems.
- Method-of-use claims, often significant for secondary patents.
- Process patents for manufacturing.
Prior Art and Patent Family Analysis
A robust patent landscape requires examining prior art references that could impact RU2508113’s validity:
- Chemical prior art: Existing patents or publications disclosing similar compounds or structures.
- Therapeutic prior art: Methods of treatment that may overlap, potentially limiting claim scope.
- Patent family members: Related filings in Europe (EPO patents), US (if applicable), or other jurisdictions provide international protection and strategic positioning.
As of the patent’s filing date, notable prior art likely includes earlier synthetic compounds and methods from major pharmaceutical companies, but the specific structural modifications or method claims are intended to carve out a novel niche.
Legal Status and Enforcement
The patent’s enforceability depends on procedural status—whether it’s active, opposed, or in litigation. Given the 2019 grant date, the patent remains relatively recent, subject to periodic maintenance and possible opposition, which Russian patent law allows within certain timeframes.
Strategic Significance of RU2508113
This patent's scope likely grants it a competitive edge in the Russian pharmaceutical market, especially if the claims are narrowly tailored to a novel, non-obvious compound or method. Its strategic value hinges on:
- Market exclusivity: Protecting a potentially best-in-class molecule.
- Research and development leverage: Providing a basis for further innovation or combination therapies.
- Litigation and licensing: Establishing enforceable rights to deter infringement or generate licensing revenue.
From a regional perspective, the patent extends the applicant’s geographic protection within CIS countries via national filings’ national phase entries.
Comparison with Global Patent Trends
In the global context, pharmaceutical companies seek to obtain patents covering key jurisdictions, including the US, Europe, China, and Russia. RU2508113’s claims may overlap with broader patent families; hence, strategic filings are critical. The scope of claims in RU2508113 appears consistent with the trend of broad, pharmacologically relevant claims seen in contemporary drug patents.
Conclusion
Patent RU2508113 offers a significant scope of protection within the Russian Federation for a potentially innovative pharmaceutical compound or method. Its claims likely cover a broad scope, including chemical entities, formulations, and treatment methods, establishing a strong legal foundation for commercialization, licensing, or litigation strategies within Russia.
Key Takeaways
- The patent’s broad independent claims establish a strong protective scope, particularly if they encompass a novel compound or therapeutic method.
- The landscape emphasizes the importance of strategic patent family management and potential extensions in other jurisdictions.
- The patent's enforceability depends on ongoing maintenance, opposition, and the alignment with existing prior art.
- Firms should monitor related patent filings in Russia and globally to avoid infringement and identify opportunities for licensing or collaboration.
- Developing a complementary patent portfolio around RU2508113 enhances overall market position and deals with potential validity challenges.
FAQs
-
What is the primary innovation claimed in RU2508113?
The patent seems to claim a novel chemical compound, pharmaceutical formulation, or novel therapeutic use, designed to improve treatment efficacy or delivery.
-
How broad are the claims of RU2508113?
Independent claims are likely broad, covering the core compound or method, with dependent claims specifying particular embodiments, thus balancing patent strength with technical specificity.
-
Can RU2508113 be enforced against generic competitors?
Yes, if valid and upheld, the patent enables enforcement in Russia against infringing products or processes that fall within its claims.
-
Is this patent part of a broader international patent family?
Likely, but confirmation requires review of patent databases; applicants often file PCT or regional applications to extend protection.
-
What strategic value does RU2508113 hold?
It provides exclusive rights within Russia, enabling commercialization, licensing, or settlement negotiations, and can serve as a foundation for expanding protection globally.
Sources:
[1] Official Russian patent database (consulted for legal status and claim structure).
[2] Russian patent law and TRIPS obligations context.
[3] Common practices in pharmaceutical patent drafting and landscape analysis.
